Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Key Abstracts from ASCO 2021 in NSCLC
AACR & ASCO 2021 – Midyear Review
Videos
Year in Review
Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Dr Mark Socinski reviews a broad variety of studies, including the evolving role of
EGFR
inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC.
Related Items
Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
By
Mark A. Socinski, MD
Dual IO 2021 - Year in Review
Dual IO 2021 - Year in Review
Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
2021 Midyear Review: Non–Small-Cell Lung Cancer
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Combination of Nivolumab and Chemotherapy in Nonmetastatic Resectable NSCLC (CheckMate-816)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Acquired Resistance Mutations After Treatment of EGFR-Mutated Metastatic NSCLC with Osimertinib plus Savolitinib (TATTON)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
American Association for Cancer Research (AACR)
AACR & ASCO 2021 – Midyear Review
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Supported through funding by
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us